BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:24 PM
Apr 30, 2008
 |  BC Extra  |  Company News

NICE issues Erbitux guidance

The U.K.'s NICE issued a final appraisal determination recommending use of Erbitux cetuximab in combination with radiotherapy to treat locally advanced squamous cell carcinoma of the head and neck (SCCHN)...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >